A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : RDI / relative dose intensity

[Related PubMed/MEDLINE]
Total Number of Papers: 227
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   RDI  (>> Co-occurring Abbreviation)
Long Form:   relative dose intensity
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). DoR, ETS, mCRC, ORR, OS, PFS, TTF
2020 A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302). AGC, CI, DCR, nab-PTX, OS, PFS, RR
2020 Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure. FN, G-CSF
2020 Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer. OR
2020 Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. CAFs, CI, HCC, HR, MVI, PFS
2020 Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B-cell lymphoma. CONUT, DLBCL, NCCN-IPI, OS, PFS
2020 Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer. OS, PSM, RFS
2020 Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer. DI, mCRPC, mCSPC, OS, PSA
2020 Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. EOC, PDS
10  2020 Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. CCI, DLBCL, EFS, OS
11  2020 Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer. AI, LM, MBC
12  2020 Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. AUC, CDCRI, NLR, NSCLC, PLR
13  2020 Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML. EFS, OS
14  2020 Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. BB, BM, CI, HR, pCR, SE, TDR
15  2020 Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study. ADRs, CTCAE, GC, NCI, TASH
16  2020 Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2). NYT, OS, PN, RFS
17  2020 Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. NSCLC, OS, PH
18  2020 Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis. BCLC, mRECIST, OR, OS, uHCC
19  2020 The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients. DFS, OS
20  2020 Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. 5'-DFUR, 5-FU, CapeOX, CES, CRC
21  2020 [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China]. FN, HR, ICERs, PEG-rhG-CSF, PP, QALYs, rhG-CSF, WTP
22  2019 A Comprehensive Review of Methods to Measure Oral Oncolytic Dose Intensity Using Retrospective Data. EHR
23  2019 Association between Comorbidity and Relative Dose Intensity in Patients with Diffuse Large B-Cell Lymphoma. DLBCL, R-CHOP
24  2019 Association between Preoperative Pelvic Irradiation and Toxicity of Subsequent Chemotherapy in Rectal Cancer. CRC
25  2019 Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer. BWL, DFS, OS, SMA
26  2019 Chemotherapy in the oldest old: Choices and outcomes. ---
27  2019 CYP2J2∗7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients. aOR, HR
28  2019 Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. HCC, MTA, PFS
29  2019 Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. CI, mCRC
30  2019 Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer. ddEC, FN
31  2019 Efficacy of prolonged elemental diet therapy after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Apilot prospective randomized trial (UMIN000004108). CG, ED, NLR, PD, PDAC, PEDG
32  2019 Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine. AZA, MDS, OS, OS, PFS
33  2019 Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. OS, PFS
34  2019 Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer. ACT, OS
35  2019 Management of Thrombocytopenia in Cancer Patients. CIT
36  2019 Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia. FCR, PFS
37  2019 Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma. DCR, mRCC, OS, PFS
38  2019 Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial. AC
39  2019 Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). AEs, CI, CTE, HRQoL, NCTE, ORR, OS, PFS, RCC
40  2019 Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders. HR, STS
41  2019 Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. OR, OS, RECIST
42  2019 Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel. ddAC, ddP
43  2019 Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. OS, PFS
44  2019 Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1). TTF, UGT, UGT1A1, WT
45  2019 The long-term social value of granulocyte colony-stimulating factors. FN, G-CSF, SV
46  2019 [A Case of Breast Cancer That Was Able to Accomplish Six Courses of TAC for Preoperative Chemotherapy Using Pegfilgrastim]. FN
47  2019 [A Comparative Study on Feasibility of SOX Therapy and SP Therapy with Short Hydration for Gastric Cancer in the Outpatient Setting]. FN, SOX, SP-SH
48  2018 Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. BTC, DFS, OS
49  2018 Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. CI, HR, OS
50  2018 Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6. 5-FU, aOR, CI, PS
51  2018 Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer. CG, NAG, NAT, PC
52  2018 Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors. ADRs, PFS, PNET
53  2018 Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma. RCC
54  2018 Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. DLTs, mRCC, OS, PFS
55  2018 Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6mg support: a single-center prospective study in Japan. EC, G-CSF
56  2018 Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative. IPTW
57  2018 Impact of relative dose intensity on bone marrow suppression induced by S-1: retrospective observational study. HR
58  2018 Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. AGC, CI, PS
59  2018 Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer. ESBC, G-CSF
60  2018 Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. MTA, OLLD, RP2D
61  2018 Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis. CI, OR, ROC
62  2018 Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. OS, PFS, RR, STS
63  2018 Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. OS, PFS
64  2018 Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. CAPOX, DLTs, FOLFOX
65  2018 The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer. DDCT, G-CSF, pCR, TN
66  2018 [Eribulin Administration Methods to Extend the Survival Time of Patients with Advanced or Recurrent Breast Cancer, Consideringthe Relative Dose Intensity, Time to Treatment Failure, Pretreatment Regimen Number, and Tumor Subtype]. OS, TTF
67  2017 Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer. ADL, BC, CRP, IL
68  2017 Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting. AIC, CIM
69  2017 Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma. RCC
70  2017 Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. DSAs and PSAs, FN, G-CSFs, ICERs, LY, NHL, PP, QALY, SP
71  2017 Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study. AEs, OS, PFS
72  2017 Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. FNH, G-CSF, KPSC, LOS, NHL
73  2017 Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. BSA, CIN, FN, G-CSF, PK
74  2017 Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy. ---
75  2017 Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens: epidemiological features, timing, predictors and clinical impacts. GEJ
76  2017 Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice. FEC-D, G-CSF
77  2017 The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer. CACI, OS, RFS
78  2017 [Effect of Pegfilgrastim Primary Prophylactic Administration on Relative Dose Intensity(RDI)in Postoperative Adjuvant Chemotherapy(TC Therapy)for Breast Cancer - A Single-Center, Retrospective Study]. ---
79  2017 [Efficacy and Safety of THP-COP for Diffuse Large B-Cell Lymphoma]. CR, DLBCL
80  2017 [Treatment Out Come of Eribulin in Patients with Advanced or Metastatic Breast Cancer Who Resistant to Anthracycline and Taxane]. CBR, ERI, ORR, OS, PFS, PPS
81  2016 Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. FN, NHL
82  2016 Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. PTX
83  2016 FOLFOX chemotherapy can safely be given to neutropenic patients with early-stage colorectal cancer for higher dose intensity and fewer visits. 5-FU, ANC, CIFN, ESCRC
84  2016 Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. CI, HR, mRCC, OS, TTF
85  2016 Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea. ESBC, FN
86  2016 Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. FN
87  2016 Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer. ER, HER2
88  2016 Prognostic factors in patients after definitive chemoradiation using involved-field radiotherapy for esophageal cancer in a phase II study. CRT, EC, GTV, IFRT, OS
89  2016 Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival. AA, ARDI, CIs
90  2016 The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity. AC, MST, OS, PDAC, PLR
91  2016 Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study. CI, EOC
92  2016 [Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy]. FN
93  2016 [Safety and Tolerance of Dose-Dense Epirubicin and Cyclophosphamide (EC) with Pegfilgrastim for Japanese Patients with Early Breast Cancer]. EC
94  2016 [The Clinical Utility of Pegfilgrastim in Combination with Adjuvant FEC(100)and TC Chemotherapy for Breast Cancer]. FN
95  2016 [Use of Pegfilgrastim in Adjuvant and Neoadjuvant Chemotherapy for Breast Cancer]. FN
96  2015 A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. ANC, DI, NE
97  2015 A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. CI, NSCLC, OS
98  2015 A review of relative dose intensity and survival in patients with metastatic solid tumors. ---
99  2015 Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. DFS, OS
100  2015 Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey. DLBCL, FN, G-CSF